Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies  Alex F. Herrera, Arturo Molina  Clinical Lymphoma, Myeloma and Leukemia  Volume 18, Issue 7, Pages 452-468.e4 (July 2018) DOI: 10.1016/j.clml.2018.05.006 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Schematic Diagram of Antibody–Drug Conjugate Structure Adapted, with permission, from Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res 2015; 32:3526-40. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 452-468.e4DOI: (10.1016/j.clml.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Mechanism of Antibody–Drug Conjugate (ADC) Drug Delivery. After Binding to the Cognate Antigen, the ADC–Antigen Complex Is Internalized by Receptor-Mediated Endocytosis. Cleavage in the Lysosome Releases the Drug Into the Cytosol. If Not Internalized, Extracellular Drug Release can Occur Reprinted, with permission, from Nature Publishing Group. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30:631-7. ©2012. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 452-468.e4DOI: (10.1016/j.clml.2018.05.006) Copyright © 2018 The Authors Terms and Conditions

Figure 3 Site-specific Versus Non–Site-Specific Conjugation and Resulting Differences in Product Distribution Adapted, with permission, from Pankowski S, Bhakta S, Raab H, Polakis P, Junutual JR. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014; 6:34-45. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 452-468.e4DOI: (10.1016/j.clml.2018.05.006) Copyright © 2018 The Authors Terms and Conditions